Humacyte annual gross margin
2025
Humacyte's gross margin was −376.05% for fiscal 2025.
View full Humacyte company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −376.05% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −203.20% | −232.44 pp |
| Q1 2026 | 2026-03-31 | −311.72% | −383.28 pp |
| Q4 2025 | 2025-12-31 | −1,844.75% | — |
| Q3 2025 | 2025-09-30 | 65.47% | — |
| Q2 2025 | 2025-06-30 | 29.24% | — |
| Q1 2025 | 2025-03-31 | 71.57% | — |
The latest reported quarter, Q2 2026, shows −203.20%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Humacyte source filings ↗